Exploring Cannabis and Psilocybin: Insights for Investors

About the Panther Group

The Panther Group is a cannabis advisory firm, operating since 2014, with a vetted marketplace of cannabis investment deals along with an extensive network of tens of thousands of cannabis professionals and investors. Panther manages three cannabis venture funds, spanning across 25+ sub-sectors of the cannabis industry. We utilize this vast ecosystem to forge genuine connections between growth-stage cannabis companies looking for access to capital and seasoned investors.

As an advisory company that acts as outsourced investor relations for the alternative medicine industries, we spend a good deal of our efforts conversing with investors on emerging trends and opportunities in the space. Recently, our discussions have pivoted toward exploring the intriguing similarities and differences in the trajectories of Psilocybin and Cannabis.

Understanding and predicting the journeys of both alternative investment verticals is paramount to what we do. By connecting the dots between emerging and established industries, we gain invaluable insights into the challenges our clients might encounter and how to align investors with opportunities.

It’s important to note that there are other psychedelics with unique characteristics and investment potential. However, for the purpose of this discussion, we have chosen to primarily focus on psilocybin due to its emerging prominence in the alternative investment landscape.

✅  Similarities:

  • Regulatory Challenges: Both Psilocybin and Cannabis have faced deeply entrenched regulatory landscapes riddled with historical prejudices. We’re now witnessing a shift, gradually clearing the path for progress.
  • Mental Health Benefits: The therapeutic potential of both substances has been underestimated, but as science delves deeper into their healing properties, new avenues for health and well-being emerge.
  • State-Level Regulation: The decentralized approach to state-level regulation creates a unique environment for experimentation and adaptation in both industries, paving the way for future growth.

Differences:

  • Administration and Infrastructure: The contrast in how these substances are administered sets them apart. Cannabis can be recommended by a doctor and used at home, while Psilocybin has been shown to be most useful in combination with therapy in a clinic setting.
  • Capitalization: The Psilocybin sector benefits from well-funded pharmaceutical companies, while cannabis entities, especially those directly involved with the plant, often face funding limitations.
  • FDA Validation: Psilocybin already has granted Breakthrough Therapy Designation by the FDA, which presents opportunities for widespread product validation, unlike cannabis products treated more as agricultural commodities.

When considering the choice between investing in the cannabis or psilocybin industry, investors are presented with unique opportunities and challenges in each space. The decision ultimately hinges on a range of factors, including the investor’s risk tolerance, investment horizon, and strategic objectives.

🌱Cannabis Investment:

  • Market Maturity: Investors have the advantage of investing in proven operators, and the potential to acquire distressed assets at attractive price points.
  • more established markets and predictable returns may find cannabis appealing.
  • Diverse Investment Avenues: There are endless ways to invest in the cannabis space, including in companies involved in cultivation, retail, medical products, manufacturing, tech, distribution, and ancillary services.
  • Wider Legalization: As cannabis gains legal recognition in various regions, investors may see opportunities for growth and expansion into new markets.
  • Steady and Consistent Demand: Cannabis enjoys a well-established and consistent demand due to its popularity for both recreational and medicinal use. Investors looking for an industry with a stable customer base and relatively steady sales may find cannabis an attractive option.

🍄Psilocybin Investment:

  • Early-Stage Opportunities: Psilocybin is still in its early stages of development, offering investors opportunity for a VC-like return profile.
  • Pharmaceutical Potential: The psilocybin sector has strong ties to pharmaceutical companies, making it attractive to investors seeking involvement in the pharmaceutical industry. There are already capitalized pharmaceutical companies willing to invest in medical solutions.
  • Low Competition: The psychedelic space has fewer established players compared to the cannabis industry, which may present opportunities for investors to get in on the ground floor.
  • Molecule Isolation: Psychedelic research benefits from clear effects through molecule isolation, while cannabis grapples with entourage effects and patent complexities. Because Psilocybin operates on a single pathway, it is easier to create a testable FDA trial opportunity and/or secure IP around the productization of that molecule.

In summary, the choice between the cannabis and psilocybin industries depends on an investor’s preferences and objectives. Cannabis offers a market with diverse opportunities, while psilocybin provides a promising landscape for early-stage investments and potential pharmaceutical breakthroughs. Both industries offer unique avenues for growth and diversification, making them compelling options for astute investors.

Contact The Panther Group to discover the best opportunities in either space for your investment portfolio: info@thepanthergroup.co.

About the Panther Group

The Panther Group is a cannabis advisory firm, operating since 2014, with a vetted marketplace of cannabis investment deals along with an extensive network of tens of thousands of cannabis professionals and investors. Panther manages three cannabis venture funds, spanning across 25+ sub-sectors of the cannabis industry. We utilize this vast ecosystem to forge genuine connections between growth-stage cannabis companies looking for access to capital and seasoned investors.

You May Also Like….

Investor Preparedness for Cannabis Operators: Best Practices for Securing Debt Financing

Investor Preparedness for Cannabis Operators: Best Practices for Securing Debt Financing

Before you begin reaching out to potential lenders, it’s essential to understand what they’re looking for. Unlike equity investors, who may be willing to take on more risk for a share of your company’s future profits, debt investors are focused on your ability to repay the loan and how to protect the principal amount they lend. They’ll want to see that your business is financially stable, cash flow-positive or close to it, and capable of managing debt responsibly.

Raising Capital in the Cannabis Industry: A Focus on Debt Solutions

Raising Capital in the Cannabis Industry: A Focus on Debt Solutions

Debt financing can be a game changer for cannabis businesses. Unlike venture capital, where you give up equity, debt financing allows you to retain full control of your company while accessing the capital you need to scale. Whether you’re looking for a loan, a line of credit, or asset-based lending, debt options can provide the flexibility cannabis operators need to navigate the tough regulatory terrain.

The Power of Collaboration and Middle Supply Chain Expertise

The Power of Collaboration and Middle Supply Chain Expertise

In the bustling world of the cannabis industry, where excitement and attention often center around the edges of the supply chain (i.e. cultivation and retail), it’s time to direct our attention to the true architects of the green revolution—the unsung heroes in the middle of the supply chain. These individuals play a pivotal role in orchestrating the intricate dance of manufacturing, packaging, storage and movement of cannabis products efficiently, making the entire industry function seamlessly.

0 Comments